/

Sociétés

Af

Non vérifié

Affinia Therapeutics

Ce que nous écrivons

BiotechnologieCardiologieIndustrie pharmaceutiqueMédecine - DiversSanté

9 communiqués de presse

Voir tous les communiqués de presse

04/03/2026

Industrie

Science

Hygiène alimentaire

Biotechnologie

Médecine - Divers

Cardiologie

Santé

Industrie pharmaceutique

Affinia Therapeutics Granted FDA Fast Track Designation for AFTX-201 as a Treatment for People Living with BAG3-Associated Dilated Cardiomyopathy (DCM)

Source

Affinia Therapeutics

Émetteur

1.00

0

18/02/2026

Science

Hygiène alimentaire

Biotechnologie

Médecine - Divers

Cardiologie

Santé

Industrie pharmaceutique

Industrie

Affinia Therapeutics Receives European Medicines Agency Orphan Drug Designation for AFTX-201 in BAG3-Associated Dilated Cardiomyopathy (DCM)

Source

Affinia Therapeutics

Émetteur

1.00

0

04/02/2026

Industrie

Science

Hygiène alimentaire

Biotechnologie

Médecine - Divers

Cardiologie

Santé

Industrie pharmaceutique

Affinia Therapeutics Announces FDA Acceptance of IND Application to Advance AFTX-201 to a Phase 1/2 Trial for the Treatment of BAG3-Associated Dilated Cardiomyopathy (DCM)

Source

Affinia Therapeutics

Émetteur

1.00

0

14/10/2025

Associations/Professionnels

Santé

Biotechnologie

Santé Publique

Finance

Industrie pharmaceutique

Cardiologie

Événements

Affinia Therapeutics to Participate in Upcoming Investor Conferences

Source

Affinia Therapeutics

Émetteur

1.00

0

07/10/2025

Santé

Technique

Biotechnologie

Médecine - Divers

Cardiologie

Affinia Therapeutics Announces Series C Financing to Advance New Class of Gene Therapies Intended to Provide Improved Safety and Efficacy

Source

Affinia Therapeutics

Émetteur

1.00

0

03/06/2025

Science

Biotechnologie

Cardiologie

Associations/Professionnels

Industrie pharmaceutique

Santé

Marché du travail

Affinia Therapeutics and DCM Foundation Announce Partnership to Increase Awareness About BAG3 Dilated Cardiomyopathy and Critical Need for Genetic Testing to Help Save Lives

Source

Affinia Therapeutics

Émetteur

1.00

0

13/05/2025

Événements

Industrie

Cardiologie

Biotechnologie

Hygiène alimentaire

Santé

Santé Publique

Industrie pharmaceutique

Science

VIH, SIDA et maladies auto-immunes

Médecine - Divers

Affinia Therapeutics Presents New Data on its Lead AFTX-201 Program in BAG3 Dilated Cardiomyopathy, BBB-Penetrant AAV Capsids, and Proprietary Manufacturing Technology at the 28th American Society of Gene & Cell Therapy 2025 Annual Meeting

Source

Affinia Therapeutics

Émetteur

1.00

0

28/04/2025

Industrie

Science

Biotechnologie

Médecine - Divers

Cardiologie

Santé

Industrie pharmaceutique

Affinia Therapeutics to Present New Data on its AFTX-201 Program in BAG3 Dilated Cardiomyopathy, BBB-Penetrant AAV Capsids, and Proprietary Manufacturing Technology at the 28th Annual American Society of Gene & Cell Therapy 2025 Annual Meeting

Source

Affinia Therapeutics

Émetteur

1.00

0

28/04/2025

Industrie

Science

Biotechnologie

Médecine - Divers

Cardiologie

Santé

Industrie pharmaceutique

Affinia Therapeutics to Present New Data on its AFTX-201 Program in BAG3 Dilated Cardiomyopathy, BBB-Penetrant AAV Capsids, and Proprietary Manufacturing Technology at the 28th Annual American Society of Gene & Cell Therapy 2025 Annual Meeting

Source

Affinia Therapeutics

Émetteur

1.00

0

Followers

0

Compatibilité

0